MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/vaccines12111209

Медицинская библиотека · Vaccines · 2024

Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10-60 Years Age Group: A Follow-Up Report Based on Phase III Clinical Trial.

Wang Yunpeng, Wu Zhiang, Li Jia, Cao Shouchun, Shi Leitai, Zhao Danhua, Mo Zhaojun, Liang Haiyan, Wu Xiaohong

СтатьяПеревод в очереди

Аннотация

Objectives

This study evaluated the 12-month persistence of rabies virus-neutralizing antibody (RVNA) following different immunization regimens of freeze-dried human rabies vaccine (Vero cells) in individuals aged 10-60 years within the Chinese population.

Methods

Number of 600 participants from phase III clinical trials who completed the fullimmunization were randomly assigned into one of three groups, four-dose experimental group, five-dose experimental group, and five-dose control group. The experimental group received the vaccine from Shandong Yeedu Biotechnology Co., while the control group used the vaccine from Liaoning Chengda Biotechnology Co., Ltd. The antibody-positive rate and geometric mean concentration (GMC) were calculated, and analysis of variance was used to compare the results among the three groups.

Results

The study included 200 participants in the four-dose experimental group, 186 in the five-dose experimental group, and 214 in the five-dose control group. Twelve months post-immunization, the overall RVNA-positive rates were 97.00%, 93.55%, and 94.86% in the four-dose experimental, five-dose control, and five-dose experimental groups, respectively. The GMCs of RVNA were 2.50, 2.05, and 2.04 IU/mL for the respective groups. The age-stratified analysis exhibited high positivity rates across age groups (≤21, 21-50, and ≥50), with rates ranging from 88.4% to 100%, and GMCs were between 1.75 and 2.61 IU/mL.

Conclusions

Twelve months after full immunization, the overall RVNA-positive rate remained high across all dosing regimens, demonstrating satisfactory immunogenicity persistence. This indicates that both the four-dose and five-dose regimens are effective in maintaining long-term immunity against rabies.

Для цитирования: Wang Yunpeng, Wu Zhiang, Li Jia, Cao Shouchun, Shi Leitai, Zhao Danhua, Mo Zhaojun, Liang Haiyan, Wu Xiaohong. Immunogenicity Persistence of Different Immunization Regimens of Rabies Vaccine in the 10-60 Years Age Group: A Follow-Up Report Based on Phase III Clinical Trial.. Vaccines. 2024. DOI: 10.3390/vaccines12111209.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.